Clemens Hinterleitner

1.0k total citations · 1 hit paper
42 papers, 627 citations indexed

About

Clemens Hinterleitner is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Clemens Hinterleitner has authored 42 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Immunology and 13 papers in Hematology. Recurrent topics in Clemens Hinterleitner's work include Immune Cell Function and Interaction (9 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Clemens Hinterleitner is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Clemens Hinterleitner collaborates with scholars based in Germany, United States and Switzerland. Clemens Hinterleitner's co-authors include Helmut R. Salih, Melanie Märklin, Stefanie Maurer, Marius Horger, Jonas S. Heitmann, Yanjun Zhou, Hans‐Georg Kopp, Ayşe Gülten Kantarcı, Emine Şalva and Gundram Jung and has published in prestigious journals such as Nature, Blood and PLoS ONE.

In The Last Decade

Clemens Hinterleitner

41 papers receiving 622 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction

2024 104 citations Corina Amor, Yu-Jui Ho et al. Nature Aging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clemens Hinterleitner Germany	14	258	229	206	107	74	42	627
Wei Xie United States	17	220 0.9×	370 1.6×	259 1.3×	203 1.9×	77 1.0×	55	986
Lingyan Ping China	15	426 1.7×	192 0.8×	219 1.1×	68 0.6×	41 0.6×	68	802
Dana E. Orange United States	15	121 0.5×	197 0.9×	214 1.0×	97 0.9×	49 0.7×	31	718
Samantha McGee United States	7	337 1.3×	229 1.0×	141 0.7×	63 0.6×	147 2.0×	8	628
Huajia Zhang United States	10	338 1.3×	322 1.4×	266 1.3×	70 0.7×	64 0.9×	11	766
Pavan Bachireddy United States	11	355 1.4×	481 2.1×	192 0.9×	90 0.8×	150 2.0×	21	1.1k
Trine Lindhardt Plesner Denmark	10	215 0.8×	213 0.9×	201 1.0×	120 1.1×	33 0.4×	30	655
Hossein Hemmatazad Switzerland	11	157 0.6×	325 1.4×	148 0.7×	43 0.4×	98 1.3×	26	689
Suk Young Park South Korea	15	232 0.9×	120 0.5×	162 0.8×	32 0.3×	67 0.9×	36	563
Alei Feng China	14	261 1.0×	168 0.7×	252 1.2×	34 0.3×	83 1.1×	27	686

Countries citing papers authored by Clemens Hinterleitner

Since Specialization

Citations

This map shows the geographic impact of Clemens Hinterleitner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clemens Hinterleitner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clemens Hinterleitner more than expected).

Fields of papers citing papers by Clemens Hinterleitner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clemens Hinterleitner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clemens Hinterleitner. The network helps show where Clemens Hinterleitner may publish in the future.

Co-authorship network of co-authors of Clemens Hinterleitner

This figure shows the co-authorship network connecting the top 25 collaborators of Clemens Hinterleitner. A scholar is included among the top collaborators of Clemens Hinterleitner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clemens Hinterleitner. Clemens Hinterleitner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perez, Almudena Chaves, Scott E. Millman, Sudha Janaki‐Raman, et al.. (2025). Metabolic adaptations direct cell fate during tissue regeneration. Nature. 643(8071). 468–477. 3 indexed citations

Amor, Corina, Yu-Jui Ho, Sandeep Nadella, et al.. (2024). Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nature Aging. 4(3). 336–349. 104 indexed citations breakdown →

Hinterleitner, Clemens, Stephan Singer, Sven Mattern, et al.. (2024). Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies. Clinical Nuclear Medicine. 49(3). 207–214. 8 indexed citations

Hinterleitner, Clemens, et al.. (2023). Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience. Cancers. 15(17). 4316–4316.

Rittig, Susanne M., Martina S. Lutz, Yanjun Zhou, et al.. (2022). Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression. Frontiers in Oncology. 12. 917834–917834. 6 indexed citations

Hagelstein, Ilona, Clemens Hinterleitner, Melanie Märklin, et al.. (2022). B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma. Frontiers in Immunology. 13. 1002898–1002898. 13 indexed citations

Kauer, Joseph, Melanie Märklin, Clemens Hinterleitner, et al.. (2022). BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of Cancer Research and Clinical Oncology. 148(10). 2759–2771. 2 indexed citations

Icheva, Vanya, Ulrich Budde, Harry Magunia, et al.. (2022). Acquired von Willebrand syndrome is common in infants with systemic-to-pulmonary shunts: Retrospective case-series. Frontiers in Pediatrics. 10. 1040128–1040128. 3 indexed citations

Märklin, Melanie, Clemens Hinterleitner, Claudia Tandler, et al.. (2022). Identification of CD105 (endoglin) as novel risk marker in CLL. Annals of Hematology. 101(4). 773–780. 3 indexed citations

10.

Zhou, Yanjun, Jonas S. Heitmann, Martina Hinterleitner, et al.. (2021). Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?. Diagnostics. 11(7). 1188–1188. 4 indexed citations

11.

Märklin, Melanie, et al.. (2021). DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis. Scientific Reports. 11(1). 18012–18012. 11 indexed citations

12.

Zhou, Yanjun, Jonas S. Heitmann, Tobias Engler, et al.. (2021). Platelet-expressed immune checkpoint regulator GITRL in breast cancer. Cancer Immunology Immunotherapy. 70(9). 2483–2496. 21 indexed citations

13.

Hinterleitner, Clemens, Yanjun Zhou, Claudia Tandler, et al.. (2021). Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression. Frontiers in Oncology. 11. 642170–642170. 13 indexed citations

14.

Hinterleitner, Clemens, et al.. (2020). Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. PLoS ONE. 15(5). e0233433–e0233433. 11 indexed citations

15.

Hagelstein, Ilona, et al.. (2020). CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation. International Journal of Hematology. 112(1). 57–64. 4 indexed citations

16.

Weller, Sandra K., Clemens Hinterleitner, Elke Malenke, et al.. (2020). The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death and Disease. 11(8). 701–701. 23 indexed citations

17.

Kauer, Joseph, Claudia Tandler, Clemens Hinterleitner, et al.. (2019). CD105 (Endoglin) as negative prognostic factor in AML. Scientific Reports. 9(1). 18337–18337. 21 indexed citations

18.

Reinert, Christian Philipp, Clemens Hinterleitner, Jan Fritz, Konstantin Nikolaou, & Marius Horger. (2018). Diagnosis of diffuse spleen involvement in haematological malignancies using a spleen-to-liver attenuation ratio on contrast-enhanced CT images. European Radiology. 29(1). 450–457. 8 indexed citations

19.

Märklin, Melanie, Jonas S. Heitmann, Michael Haap, et al.. (2018). A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia. Journal of Visualized Experiments. 3 indexed citations

20.

Hinterleitner, Clemens, Stefan Wirths, Stefanie Bugl, et al.. (2017). Platelet Programmed Cell Death Ligand 1 (pPDL-1) Is a Prognostic Marker in Advanced Lung Cancer. Blood. 130. 3610–3610. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact